What do boxers and swing traders have in common? Avoiding big hits and striking at opportunities when they come. Here's how.
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a recommendation by the European Medicines Agency (EMA) at the end of May. The debilitating disease is also known as 'smoker's lungs' because in western countries it primarily affects cigarette smokers.